Status:
COMPLETED
Remote Ischemic Preconditioning on the Prognosis of Patients With Elective PCI Using Drug-coated Balloon
Lead Sponsor:
Henan Institute of Cardiovascular Epidemiology
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Drug-coated balloon is being used more and more widely for the advantage of intervention without implantation. But the balloon needs to be released long enough to be effective. Prolonged balloon dila...
Detailed Description
Some patients receiving PCI cannot tolerate the symptoms of myocardial ischemia caused by the release of the drug balloon for a long time and even lead to the occurrence of adverse events.RIPC was fou...
Eligibility Criteria
Inclusion
- Diameter stenosis\>=50% by visual estimation intend to undergo drug-coated balloon implantation
- Target vessel diameter\> 2.5mm
Exclusion
- Chronic Total Obstructive lesion
- Diagnose patients with acute myocardial infarction \<24 hours
- Can't tolerate or not suitable for RIPC
- Severe hepatic and renal insufficiency
- Expected survival \<1 year
- Severe calcification needing rotational atherectomy
- Intolerable to dual antiplatelet therapy
Key Trial Info
Start Date :
February 24 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2023
Estimated Enrollment :
430 Patients enrolled
Trial Details
Trial ID
NCT04766749
Start Date
February 24 2021
End Date
May 20 2023
Last Update
December 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuwai central China cardiovascular Hospital
Zhengzhou, Henan, China